Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- GSKN.MX
- Price
- 791.00
- Stock movement up
- +- (%)
- Company name
- GlaxoSmithKline plc
- Exchange
- (MX ,
- Currency
- MXN )
- Sector
- Healthcare >Drug Manufacturers - General
- Markedsværdi
- 1613.85B
- Ent værdi
- 1655.18B
- Pris/omsætning
- 51.32
- Pris/bog
- 117.20
- Udbytte afkast
- -
- Udbyttevækst
- -
- Vekst år
- -
- FCF-udbetaling
- 45.34%
- Efterfølgende P/E
- 400.16
- Fremtidig P/E
- -
- PEG
- -
- EPS-vekst
- 10.73%
- 1 års afkast
- 4.55%
- 3 års afkast
- -3.14%
- 5 års afkast
- -3.29%
- 10 års afkast
- 1.92%
Senest opdateret: 2025-06-22
UDBYTTE
GSKN.MX betaler ikke udbytte
VÆRDIANSÆTTELSE
Værdiansættelsesforhold
Loading...
Værdiansættelsesforhold-data
| Efterfølgende P/E | 400.16 |
| Pris til OCF | 215.78 |
| Pris til FCF | 310.71 |
| Pris til EBITDA | - |
| EV i forhold til EBITDA | - |
Værdiansættelse (salg/bogført værdi)
Loading...
Værdiansættelse (salg/bogført værdi)-data
| Pris til omsætning | 51.32 |
| Pris til egenkapital | 117.20 |
| EV i forhold til salg | 52.64 |
ØKONOMI
Pr. aktie
Loading...
Data pr. aktie
| Aktuelt antal aktier | 2.04B |
| EPS (TTM) | 0.99 |
| FCF pr. aktie (TTM) | 1.27 |
Resultatopgørelse
Loading...
Resultatopgørelse-data
| Omsætning (TTM) | 31.45B |
| Bruttofortjeneste (TTM) | 22.66B |
| Driftsindkomst (TTM) | 6.26B |
| Nettoindkomst (TTM) | 4.03B |
| EPS (TTM) | 0.99 |
| EPS (1 år frem) | - |
Marginer
Loading...
Marginer-data
| Bruttomargin (TTM) | 72.07% |
| Driftsmargin (TTM) | 19.90% |
| Fortjenstmargin (TTM) | 12.83% |
Balance
Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Balancedata
| Kontanter | 2.96B |
| Nettotilgodehavender | 7.26B |
| Omsætningsaktiver i alt | 16.76B |
| Goodwill | 6.96B |
| Immaterielle aktiver | 15.47B |
| Ejendomme, anlæg og udstyr | 9.82B |
| Sum aktiver | 58.07B |
| Kreditor | 14.24B |
| Kortfristet/nuværende langsigtet gæld | 0.00 |
| Summen af kortfristede forpligtelser | 20.34B |
| Sum gæld | 44.30B |
| Aktionærernes egenkapital | 13.77B |
| Materielle nettoaktiver | 0.00 |
Likviditet
Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Kontantstrøm-data
| Likviditet fra driften (TTM) | 7.48B |
| Investeringsudgifter (TTM) | 2.29B |
| Fri pengestrøm (TTM) | 5.19B |
| Udbetalt udbytte (TTM) | 2.35B |
Finansiel indkomst
Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Data om finansiel indkomst
| Egenkapitalafkast | 29.29% |
| Afkast af aktiver | 6.95% |
| Afkast af investeret kapital | 29.29% |
| Kontant afkast af investeret kapital | 37.72% |
INFORMATION OM AKTIER
Aktiediagram
Loading...
Aktiekurs-data
| Åbning | 791.00 |
| Daglig høj | 791.00 |
| Daglig lav | 791.00 |
| Daglig volumen | 0K |
| Højeste gennem alle tider | 1061.99 |
| 1 års analytiker estimat | - |
| Beta | 0.33 |
| EPS (TTM) | 0.99 |
| Udbytte pr. aktie | - |
| Ex-div dato | 16 May 2025 |
| Næste dato for resultatpræsentation | 30 Jul 2025 |
Nedsidepotensial
Loading...
Nedsidepotensial-data
| GSKN.MX | S&P500 | |
| Nuværende prisfald fra top notering | -25.52% | -2.53% |
| Højeste prisfald | -45.20% | -56.47% |
| Højeste efterår dato | 12 Sep 2023 | 9 Mar 2009 |
| Gennemsnitlig fald fra toppen | -18.91% | -11.04% |
| Gennemsnitlig tid til nyt højdepunkt | 29 days | 12 days |
| Maks. tid til nyt højdepunkt | 1298 days | 1805 days |
OPLYSNINGER OM VIRKSOMHEDEN
Markedsværdi
1613.85B
Markedsværdi kategori
Large-cap
Beskrivelse
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development; two strategic collaborations with Relation to advance therapeutics for fibrotic diseases and osteoarthritis; and multi-target strategic alliance with GSK to develop breakthrough treatments for people afflicted with Parkinson's disease; as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.dom.
Personale
70212
Hjemmeside
Investor relationer
-
SEC-indsendelser
Adm. direktør
Land
Mexico
By
Aktietype
-
CCC-status
-
Utbyttefrekvens
-
ARRANGEMENTER OG PRÆSENTATIONER
ArrangementerPræsentationer
Loading...
FORSTÅ FORRETNINGEN
Loading...
NYHEDER OM VIRKSOMHEDEN
Alle nyhederPressemeddelelser
PHILADELPHIA, July 10, 2025--GSK begins shipping influenza vaccine doses for the 2025-26 flu season.
10. juli 2025
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
9. juli 2025
GSK is witnessing increased sales growth of its Specialty Medicines unit, a trend expected to continue through the rest of 2025.
9. juli 2025
GILD jumps 27.2% in six months as FDA nod for twice-yearly HIV drug Yeztugo boosts its HIV franchise and growth outlook.
8. juli 2025
The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of inco...
8. juli 2025
Hansa Biopharma AB, "Hansa" (NASDAQ Stockholm: HNSA) today announced that Dr. Richard Philipson has been appointed Chief Medical Officer (CMO) effective 14 July. Dr Philipson will report to CEO Renée ...
8. juli 2025
Overseas equities are outperforming domestic shares for the first time in about 15 years, and some financial pros say it’s time for U.S. investors to get back in.
4. juli 2025
The House Judiciary Committee has subpoenaed Dr. Philip Dormitzer, a former Pfizer Inc. (NYSE:PFE) executive, in connection with an investigation into claims that the company intentionally delayed the...
4. juli 2025
Glaxo (GSK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
3. juli 2025
Moderna stock popped Wednesday after the CDC recommended the company's RSV vaccine for at-risk adults in their 50s.
3. juli 2025
Næste side